Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | MT-6402 |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | MT-6402 | Case Reports/Case Series | Actionable | In a Phase I trial, MT-6402 treatment led to an antitumor immune response and decreased metastatic bone lesions in a CD274 (PD-L1)-positive non-small cell lung cancer patient with osseous metastases (Cancer Res 2022;82(12_Suppl):Abstract nr CT152). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Phase I study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing advanced solid tumors | Full reference... |